SCHEMBL4056451

SCHEMBL4056451

FC(F)(F)c1ccc(CCc2nc3ncc(-c4ccco4)cc3[nH]2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.44
NOS3 P29474 1/20 0.40
NOS1 P29475 1/20 0.40
NOS2 P35228 1/20 0.40
GABRA1 P14867 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
GABRA2 P47869 1/20 0.40
GABRA4 P48169 1/20 0.40
GABRA6 Q16445 1/20 0.40
ADORA2A P29274 7/20 0.39
ADORA1 P30542 5/20 0.39
PDE10A Q9Y233 1/20 0.39
PIK3R1 P27986 1/20 0.38
PIK3CA P42336 1/20 0.38
ADORA3 P0DMS8 4/20 0.37
QPCT Q16769 2/20 0.36
NTRK1 P04629 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4060685 0.91 KIT (0.42) TRPV1NOS3NOS1NOS2GABRA1
SCHEMBL4054880 0.88 NOS3 (0.42) NOS3NOS1NOS2ADORA2APIK3R1
SCHEMBL4060650 0.87 NOS3 (0.49) NOS3NOS1NOS2ADORA2AADORA1
SCHEMBL4053237 0.86 NOS3 (0.42) NOS3NOS1NOS2ADORA2AADORA1
SCHEMBL4058313 0.86 NOS1 (0.44) NOS3NOS1NOS2ADORA2AADORA1
SCHEMBL4059226 0.84 NOS3 (0.53) TRPV1NOS3NOS1NOS2PDE10A
SCHEMBL4053616 0.83 NOS3 (0.40) NOS3NOS1NOS2ADORA2AADORA1
SCHEMBL4055225 0.83 NOS1 (0.42) NOS3NOS1NOS2ADORA2APDE10A
SCHEMBL13608668 0.83 TRPV1 (0.42) TRPV1GABRA1GABRG2GABRB3GABRA5
SCHEMBL4055769 0.83 NOS1 (0.54) NOS3NOS1NOS2ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B TRPV1 2690/4885NOS3 907/4885NOS1 879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.